Helpdesk

Sales contact

Home > Resources > How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

Last updated: October 24, 2025

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

Subscribe to our newsletter

Strengthening Endpoint Reliability: An Interview with Estelle Haenel, Chief Medical...

Kayentis and RWS join forces to improve data confidence in...

What if eCOA could elevate your next rare disease trial?

Elevating rare disease clinical trials through eCOA – From patient...

Overcoming rare disease trial challenges: the strategic impact of eCOA

Kayentis and Perceptive eClinical partner to tackle increasing digital system...

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events